JP2005530819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530819A5 JP2005530819A5 JP2004512660A JP2004512660A JP2005530819A5 JP 2005530819 A5 JP2005530819 A5 JP 2005530819A5 JP 2004512660 A JP2004512660 A JP 2004512660A JP 2004512660 A JP2004512660 A JP 2004512660A JP 2005530819 A5 JP2005530819 A5 JP 2005530819A5
- Authority
- JP
- Japan
- Prior art keywords
- bone
- composition
- composition according
- growth
- treatment comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 14
- 210000000988 Bone and Bones Anatomy 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000002708 enhancing Effects 0.000 claims 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 208000006386 Bone Resorption Diseases 0.000 claims 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 3
- 230000024279 bone resorption Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 229940062527 Alendronate Drugs 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 206010007709 Cartilage disease Diseases 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 206010061762 Chondropathy Diseases 0.000 claims 1
- 229960002286 Clodronic Acid Drugs 0.000 claims 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- 229940009626 Etidronate Drugs 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 1
- 229940015872 Ibandronate Drugs 0.000 claims 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims 1
- 210000002997 Osteoclasts Anatomy 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 208000008425 Protein Deficiency Diseases 0.000 claims 1
- 229940089617 Risedronate Drugs 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 240000006394 Sorghum bicolor Species 0.000 claims 1
- 229940019375 Tiludronate Drugs 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims 1
- 230000000123 anti-resoprtive Effects 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- 230000003412 degenerative Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 235000019713 millet Nutrition 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 230000000921 morphogenic Effects 0.000 claims 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- 229950010733 neridronic acid Drugs 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 230000000790 osteoblast Effects 0.000 claims 1
- 230000002148 osteoclast Effects 0.000 claims 1
- 230000002188 osteogenic Effects 0.000 claims 1
- 230000000010 osteolytic Effects 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 201000000981 primary hyperparathyroidism Diseases 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960005324 tiludronic acid Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
Claims (12)
- 脊椎動物における骨形成または骨無機質密度を増強するための組成物であって、ビスホスホネートおよび一酸化窒素(NO)放出化合物を含む、組成物。
- 前記ビスホスホネートが、アレンドロネート、パミドロネート、クロドロネート、ゾレドロネート、リセドロネート、エチドロネート、イバンドロネート、チルドロネート、ネリドロネート、オルパドロネート、イカドロネートまたはYH529である、請求項1に記載の組成物。
- 前記脊椎動物被験体が、哺乳動物である、請求項1または2に記載の組成物。
- 前記哺乳動物が、ヒトである、請求項3に記載の組成物。
- 薬学的に受容可能なキャリアまたは賦形剤をさらに含む、請求項1〜4のいずれか1項に記載の組成物。
- 前記動物が、骨粗鬆症、骨折もしくは骨欠乏、原発性副甲状腺機能亢進症および続発性副甲状腺機能亢進症、骨溶解性骨疾患、形成術後、補綴関節手術後の変性性関節状態、歯移植後または軟骨の障害もしくは傷害を有する/罹患している、請求項1〜5のいずれか1項に記載の組成物。
- 骨増殖を増強するかまたは骨吸収を減少させるさらなる薬剤と組み合わせて投与される、請求項1〜6のいずれか1項に記載の組成物。
- 前記薬剤が、骨形態形成タンパク質、成長ホルモン、エストロゲン、スタチン、ビスホスホネート、骨原性因子、抗吸収剤、軟骨由来の形態形成タンパク質、分化因子、骨増殖刺激化合物、NF−κBインヒビター、プロテアソームインヒビター、プロテアソーム産生インヒビターまたはステロイドである、請求項7に記載の組成物。
- 前記処置は、骨芽細胞の刺激を含む、請求項1〜8のいずれか1項に記載の組成物。
- 前記処置は、破骨細胞の阻害を含む、請求項1〜8のいずれか1項に記載の組成物。
- 請求項1または2に記載の結合体、および骨増殖を増強するかまたは骨吸収を減少させるさらなる薬剤を含む組合せ製品。
- 脊椎動物を処置することにおいて同時に、別個にまたは連続して使用するための、請求項1または2に記載の結合体、および骨増殖を増強するかまたは骨吸収を減少させるさらなる薬剤を含む製品であって、ここで該処置は、骨形成の刺激を含む、製品。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37789802P | 2002-05-02 | 2002-05-02 | |
PCT/US2003/013696 WO2003105752A2 (en) | 2002-05-02 | 2003-05-02 | Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate) |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005530819A JP2005530819A (ja) | 2005-10-13 |
JP2005530819A5 true JP2005530819A5 (ja) | 2006-06-22 |
Family
ID=29736069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004512660A Pending JP2005530819A (ja) | 2002-05-02 | 2003-05-02 | 一酸化窒素を放出するビスホスホネート結合体(no−ビスホスホネート)を使用して骨増殖を刺激するための、方法および組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US7288535B2 (ja) |
EP (1) | EP1539185A4 (ja) |
JP (1) | JP2005530819A (ja) |
AU (1) | AU2003231255A1 (ja) |
CA (1) | CA2485090A1 (ja) |
WO (1) | WO2003105752A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
NZ571113A (en) * | 2005-11-17 | 2012-02-24 | Biomimetic Therapeutics Inc | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
CA2641860C (en) * | 2006-02-09 | 2015-07-14 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
CA2656278C (en) | 2006-06-30 | 2016-02-09 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating rotator cuff injuries |
US9161967B2 (en) * | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
WO2008073628A2 (en) | 2006-11-03 | 2008-06-19 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures |
AU2009212151C1 (en) * | 2008-02-07 | 2015-09-17 | Biomimetic Therapeutics, Llc | Compositions and methods for distraction osteogenesis |
NZ602861A (en) * | 2008-09-09 | 2014-03-28 | Biomimetic Therapeutics Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
WO2010102266A1 (en) * | 2009-03-05 | 2010-09-10 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
JP5878477B2 (ja) | 2010-01-15 | 2016-03-08 | ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー | 骨の治癒を加速するためのバナジウム化合物の使用 |
EP2538791B1 (en) | 2010-02-22 | 2015-04-08 | BioMimetic Therapeutics, LLC | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
WO2012079024A2 (en) | 2010-12-10 | 2012-06-14 | University Of Medicine And Dentistry Of New Jersey | Implantable devices coated with insulin-mimetic agent composites and methods thereof |
WO2013006798A1 (en) | 2011-07-06 | 2013-01-10 | University Of Medicine And Dentistry Of New Jersey | Vandium compounds as therapeutic adjuncts for cartilage regeneration and repair |
US20140322292A1 (en) * | 2010-12-10 | 2014-10-30 | Rutgers, The State University Of New Jersey | Insulin-mimetics as therapeutic adjuncts for bone regeneration |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
US20170087175A1 (en) * | 2015-09-30 | 2017-03-30 | Elwha Llc | Nitric oxide-modulating bone-targeting complexes |
US20190275160A1 (en) | 2016-03-15 | 2019-09-12 | The Regents Of The University Of California | Bone-targeting therapeutic conjugate and methods of making and using the same |
KR20180115979A (ko) * | 2017-04-14 | 2018-10-24 | 연세대학교 산학협력단 | 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5121253A (en) * | 1990-12-28 | 1992-06-09 | Waintroob Stewart B | Visor for a computer terminal display and method |
IT1246778B (it) * | 1991-04-12 | 1994-11-26 | Boehringer Mannheim Italia | Nitrosocarbamoil derivati di acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5280040A (en) | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
US5898038A (en) | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
US6214812B1 (en) * | 1998-04-02 | 2001-04-10 | Mbc Research, Inc. | Bisphosphonate conjugates and methods of making and using the same |
IT1303672B1 (it) * | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali nitrati di farmaci attivi nei disordini ossei |
US6121253A (en) * | 1998-11-20 | 2000-09-19 | Merck Frosst Canada & Co. | Prostaglandin conjugates for treating or preventing bone disease |
WO2000051597A1 (en) * | 1999-03-05 | 2000-09-08 | Merck Frosst Canada & Co. | Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss |
IT1311924B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
-
2003
- 2003-05-02 AU AU2003231255A patent/AU2003231255A1/en not_active Abandoned
- 2003-05-02 US US10/428,309 patent/US7288535B2/en not_active Expired - Fee Related
- 2003-05-02 CA CA002485090A patent/CA2485090A1/en not_active Abandoned
- 2003-05-02 JP JP2004512660A patent/JP2005530819A/ja active Pending
- 2003-05-02 WO PCT/US2003/013696 patent/WO2003105752A2/en not_active Application Discontinuation
- 2003-05-02 EP EP03724391A patent/EP1539185A4/en not_active Withdrawn
-
2007
- 2007-10-30 US US11/929,701 patent/US20080108588A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005530819A5 (ja) | ||
NZ545804A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate | |
AU2002244520B2 (en) | A drug for use in bone grafting | |
Fleisch | Bisphosphonates: mechanisms of action and clinical use in osteoporosis-an update | |
JP2002529490A5 (ja) | ||
JP2016527006A5 (ja) | ||
CA2438848A1 (en) | Compositions for delivering bisphosphonates | |
RU2006140888A (ru) | Лекарственные формы на основе бисфосфонатов | |
RU2006136790A (ru) | 8-(2-гидроксифенокси)октилдиетаноламин и его соли для доставки активных агентов | |
AU693541B2 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
JP2004527479A5 (ja) | ||
JP2009522369A5 (ja) | ||
CA2910398A1 (en) | Methods, systems, and compositions for promoting bone growth | |
CA2223450A1 (en) | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices | |
RU2009134119A (ru) | Инъецируемый кальций-фосфатный цемент, высвобождающий ингибитор резорбции костной ткани | |
JP2009541475A5 (ja) | HMG−CoA還元酵素阻害剤およびファルネシルピロリン酸合成酵素阻害剤を含む治療剤 | |
AU2002244520A1 (en) | A drug for use in bone grafting | |
RU2008132150A (ru) | Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом | |
CA2415228A1 (en) | Treatment of bone diseases | |
JP2004526747A5 (ja) | ||
RU2006110736A (ru) | Комбинация, содержащая n-(3-метокси-5-метилпиразин-2-ил)-2-(1, 3, 4-оксадиазол-2-ил)пиридин-3-сульфонамид и lhrh- аналог и/или бифосфонат | |
Serra et al. | Oral implants in patients receiving bisphosphonates: a review and update | |
AR039548A1 (es) | Vehiculos solidos inyectables de acido hialuronico para la administracion de proteinas osteogenicas | |
HK1009246A1 (en) | Wet granulation formulation for biphosphonic acids | |
ATE357921T1 (de) | Alendronate zur behandlung von osteoporose |